Het partnerschap zal 54gene’s sequencing-gebaseerd onderzoek en moleculaire diagnostische mogelijkheden uitbreiden met de nadruk op het verbeteren van gezondheidsresultaten door middel van precisiegeneeskunde

CAMBRIDGE, Engeland– (BUSINESS WIRE) – Illumina, Inc. (NASDAQ: ILMN) kondigde vandaag een samenwerking aan met 54gene, een gezondheidstechnologiebedrijf dat tot doel heeft de capaciteiten van precisiegeneeskunde in Afrika te vergroten door middel van onderzoek, geavanceerde moleculaire diagnostiek en klinische programma’s. Het partnerschap ondersteunt de oprichting van een nieuwe genetica-faciliteit in Lagos, Nigeria, uitgerust met een reeks van Illumina’s geavanceerde sequencing- en high-density microarray-technologieplatforms, die genetische informatie zullen genereren voor gezondheidsonderzoek en medicijnontwikkeling.

Afrika bevat meer genetische diversiteit dan enig ander continent, omdat het Afrikaanse genoom het oudste menselijke genoom is. Toch wordt geschat dat minder dan 3% van de geanalyseerde genomen afkomstig is van Afrikanen, waardoor het een potentieel rijke bron van nieuwe genetische informatie voor onderzoek op het gebied van gezondheid en geneesmiddelenonderzoek is, die 54gene wil gebruiken als een wereldwijd onderzoeksmiddel en tegelijkertijd ervoor zorgt dat Afrikanen profiteren van het snijden. -edge medische innovaties.

Illumina Collaborates With 54gene in the Creation of a World-Class Genomics Facility in Nigeria

Partnership will expand 54gene’s sequencing-based research and molecular diagnostics capabilities with a focus on improving health outcomes through precision medicine

CAMBRIDGE, England–(BUSINESS WIRE)– Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration with 54gene, a health technology company whose mission is to advance precision medicine capabilities in Africa through research, advanced molecular diagnostics and clinical programs. The partnership will support the establishment of a new genetics facility in Lagos, Nigeria, equipped with a suite of Illumina’s cutting-edge sequencing and high-density microarray technology platforms, which will generate genetic information for health research and drug development.

Africa contains more genetic diversity than any other continent because the African genome is the oldest human genome. Yet it is estimated that fewer than 3% of the genomes analyzed come from Africans, making it a potentially rich source of new genetic information for health and drug discovery research, which 54gene intends to leverage as a global research resource while ensuring Africans benefit from cutting-edge medical innovations.

Paula Dowdy, SVP, General Manager EMEA, Illumina, said, “It’s incredibly important to ensure equitable access to genomic sequencing technology across the world so that genomes can be interpreted in the context of global diversity. Through partnerships such as this with 54gene, we aim to remove barriers of access to sequencing and expand the benefits of genomics to as many people as possible.”

54gene Founder and CEO Dr. Abasi Ene-Obong said, “The addition of Illumina’s cutting-edge technology to our research and diagnostic capabilities is a critical step for 54gene in fulfilling our mission of equalizing access to precision medicine. This is part of our wider commitment to build capacity and infrastructure in Africa, which will allow us to significantly expand genomics research, while also improving health outcomes on the continent. Alongside our many partners in the African medical and scientific community, we want to make advanced molecular diagnostics more accessible to the region, while creating hundreds of skilled jobs in molecular biology and bioinformatics.”

Through the partnership, African samples stored in 54gene’s de-identified biobank, will be genotyped, sequenced and analyzed without the need to send samples overseas, reflecting Illumina’s commitment to enabling Africa to expand its genomic capabilities. Having local infrastructure will reduce costs and turnaround time for test results. Illumina will also deliver its renowned training to support the use of its sequencing and microarray equipment and ensure ongoing support for 54gene’s growing team of molecular scientists.

###

To learn more, visit the Illumina News Center.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

About 54gene

54gene is a health technology company advancing the state of healthcare through large-scale discovery and translational research, advanced molecular diagnostics, and inclusive clinical programs for the benefit of Africans and the global population. Founded in 2019, 54gene utilizes human genetic data derived from diverse African populations, to improve the development, availability, and efficacy of medical products and diagnostics that will prove beneficial to Africans and the wider global population.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are our ability to expand the adoption and use of genomics, especially in clinical settings, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005204/en/

Contacts

Investors:
Jacquie Ross, CFA

858-255-5243

ir@illumina.com

Media:
Karen Birmingham, PhD

+44 7500 105665

kbirmingham@illumina.com